Anthony P. Mack - May 18, 2022 Form 4 Insider Report for Virpax Pharmaceuticals, Inc. (VRPX)

Role: Chief Executive Officer, Director
Signature: /s/ Christopher Chipman, attorney-in-fact
Stock symbol: VRPX
Transactions as of: May 18, 2022
Transactions value $: $101,505
Form type: 4
Date filed: 5/20/2022, 06:15 PM
Previous filing: Feb 25, 2022
Next filing: Feb 7, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	VRPX	Common Stock, $0.00001 par value	Purchase	$102K	+75.8K	+42.84%	$1.34	253K	May 18, 2022	Direct	F1
holding	VRPX	Common Stock, $0.00001 par value						2.73M	May 18, 2022	By Virpax Pharmaceuticals, LLC	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The price reported in Column 4 is a weighted average price. These shares of Common Stock were purchased in multiple transactions at prices ranging from $1.32 to $1.37 per share, inclusive. The Reporting Person undertakes to provide to Virpax Pharmaceuticals, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein.
F2	The Reporting Person owns 88.8888% of the outstanding member units of Virpax Pharmaceuticals, LLC. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein.

Content

The price reported in Column 4 is a weighted average price. These shares of Common Stock were purchased in multiple transactions at prices ranging from $1.32 to $1.37 per share, inclusive. The Reporting Person undertakes to provide to Virpax Pharmaceuticals, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein.

The Reporting Person owns 88.8888% of the outstanding member units of Virpax Pharmaceuticals, LLC. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein.